Risperidone. A review of its pharmacology and therapeutic potential in the treatment of schizophrenia

S Grant, A Fitton


Risperidone, a benzisoxazol derivative, is a novel antipsychotic agent which combines potent serotonin (5-hydroxytryptamine) 5-HT2 and dopamine D2 receptor antagonism. Development of the drug was stimulated by reports that the selective serotonin 5-HT2 antagonist ritanserin improved the negative symptoms of schizophrenia and decreased extrapyramidal symptoms when combined with haloperidol. The relatively low incidence of extrapyramidal symptoms with risperidone may reflect a preferential action on mesolimbic rather than nigrostriatal dopaminergic pathways. Recent clinical investigation suggests that risperidone is of at least comparable efficacy to haloperidol and perphenazine in improving the symptoms of acute and chronic schizophrenia on short term administration. Advantages offered by risperidone over haloperidol include a faster onset of antipsychotic action, a lower incidence of extrapyramidal effects and possibly greater efficacy against the negative symptoms of schizophrenia. If these benefits prove to be maintained during long term therapy, risperidone is likely to make a significant contribution to the treatment of schizophrenia.


Oct 1, 1996·Journal of Clinical Pharmacy and Therapeutics·I R de OliveiraJ Bacaltchuk
Jul 1, 1997·The Annals of Pharmacotherapy·D S Ravin, J W Levenson
May 4, 1999·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·O Blin
Dec 5, 2000·Behavioural Pharmacology·B Scatton, D J Sanger
Dec 4, 2003·CNS Drug Reviews·Shiho HirotaShigeru Okuyama
Jul 2, 2004·Therapeutic Drug Monitoring·Christoph HiemkeMatthias J Müller
Nov 27, 2004·European Archives of Psychiatry and Clinical Neuroscience·Michael RiedelH J Möller
Apr 6, 2006·Palliative & Supportive Care·Soenke Boettger, William Breitbart
Mar 16, 2007·Acta Psychiatrica Scandinavica·J EberhardS Levander
Jun 15, 2012·AAPS PharmSciTech·Yardi SaibiHidehisa Tachiki
Mar 13, 2014·Journal of Drug Delivery·Susan D'SouzaPatrick P Deluca
Jun 20, 2018·Clinical Pharmacokinetics·Massimo C MauriAlfredo Carlo Altamura
Jul 31, 2001·Journal of Clinical Psychopharmacology·C L DeVane, C B Nemeroff
Apr 5, 2003·The Journal of Pharmacology and Experimental Therapeutics·Craig R RushLon S Hays
Jan 20, 2004·CNS Drugs·Tracy Swainston Harrison, Karen L Goa
Apr 24, 2007·CNS Drugs·Lily P H Yang, Greg L Plosker
Aug 22, 2018·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Piotr StępnickiAgnieszka A Kaczor
Mar 25, 2019·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·Mohamed S ZulfarinaIsa Naina-Mohamed
Jan 8, 2004·Journal of Clinical Psychopharmacology·Edmund P HarriganMichelle Middle
Mar 14, 2001·European Psychiatry : the Journal of the Association of European Psychiatrists·Massimo C MauriP Papa
May 31, 2003·Journal of Cardiovascular Pharmacology·Benoit DroletJacques Turgeon
Dec 1, 1996·Journal of Clinical Psychopharmacology·C Heimberg, A S Yearian
Feb 11, 1999·The Annals of Pharmacotherapy·J S MarkowitzT R Moore
Oct 24, 2007·Acta Psychiatrica Scandinavica. Supplementum·E LindströmS Levander
Dec 17, 2002·Pharmazie in unserer Zeit·Sebastian Härtter, Christoph Hiemke
Nov 12, 2009·Clinical Pharmacokinetics·Shu-Feng Zhou
Sep 1, 1999·Acta Neuropsychiatrica·M J Hoes
Dec 18, 2013·Pharmacogenomics·Evangelia Eirini TsermpiniGeorge P Patrinos
May 17, 2019·Drug Development and Industrial Pharmacy·Rajalakshmi RukmangathenPrasanna Raju Yalavarthi

Related Concepts

Antipsychotic Effect
Biochemical Pathway
Central Nervous System
Assay OF Haloperidol
Serotonin Measurement
Synaptic Transmission
Extrapyramidal Sign
Process of Absorption

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here